. 2009 Jul 21;100(11):1999–2005. doi: 10.1111/j.1349-7006.2009.01294.x

Table 1.

Promising small molecules that disrupt osteoclast function

Principal small molecules	Target molecule	Stage of development	Reference
Etidronate, Clodronate	ATP‐requiring molecules	Marketed	⁽ ⁹ ⁾
Alendronate, Zoledronate	FPP synthase	Marketed	⁽ ⁹ ⁾
MK‐0822, AAE581	Cathepsin K	Clinical	⁽ ¹² ⁾
AZD0530, CGP76030	c‐Src	Clinical, Preclinical	⁽ ¹⁹ ⁾
L‐000845704, SB265123	α_Vβ₃ integrin	Clinical, Preclinical	⁽ 23, 57 ⁾
FR202126, Iejimalide A, B	V‐ATPase	Preclinical	⁽ 26, 30 ⁾
NS3736	ClC‐7 Cl⁻ channel	Preclinical	⁽ ³² ⁾
KN‐93	CaMKIV	Preclinical	⁽ ³³ ⁾
LFM‐A13	Btk/Tec	Preclinical	⁽ ³⁴ ⁾
(‐)‐DHMEQ, PDTC	NF‐κB	Preclinical	⁽ 35, 36 ⁾
Reveromycin A	IleRS	Preclinical	⁽ 43, 44 ⁾

CaMKIV, Ca²⁺/calmodulin‐dependent kinase IV; (‐)‐DHMEQ, (‐)‐dehydroxymethylepoxyquinomicin; FPP, farnesyl pyrophosphate; IleRS, isoleucyl‐tRNA synthetase; PDTC, pyrrolidine dithiocarbamate.